FeaturedNews LUMC & Batavia Biosciences Burst the Bubble Severe Combined Immunodeficiency (SCID) disease affects 1 in 35,000 newborns annually, of which approximately 145…Aaron Ogdahl29 November 2022
BlogFeaturedViral vaccinesViral vectors Driving down COGs of viral vector-based biopharmaceuticals How do you keep cost of goods (COGs) for viral vector-based medicines within reason to…Aaron Ogdahl8 November 2022
News Eize De Boer featured as prominent speaker at ATMP-themed TechTalks Eize De Boer showed us what it takes to realize a new facility for Batavia Biosciences designed for…Aaron Ogdahl28 October 2022
Events CPHI Frankfurt Date: Nov 1-3 Location: Frankfurt, Germany Contact: Pieter-Jan Vos It’s time for one of the…Aaron Ogdahl23 September 2022
News Batavia Biosciences Optimizes Global Quality Assurance with Veeva Vault Quality Suite BARCELONA, Spain — September 15, 2022- Veeva Systems (NYSE: VEEV) today announced Batavia Biosciences selected…Aaron Ogdahl15 September 2022
Events BIO-Europe Leipzig Date: 24 - 26 October 2022 Location: Leipzig, Germany Contact: Pieter-Jan Vos Are your joining…Aaron Ogdahl15 September 2022
Events ESGCT Edinburgh, Scotland 2022 Date: 11-14 October Location: Edinburgh, Scotland Contact: Pieter-Jan Vos Meet us at the 29th European…Aaron Ogdahl14 September 2022
Events World Vaccine Congress 2022 – Barcelona, Spain Date: 11-14 October Location: Barcelona, Spain Contact: Bjorn te Boekhorst Meet us at the World Vaccine…Aaron Ogdahl13 September 2022
News Batavia manufactures LASV vaccine candidate for IAVI who today announced the first vaccinations of their Lassa fever vaccine candidate Batavia Biosciences would like to congratulate IAVI on their press release, as today they've announced volunteers…Aaron Ogdahl31 August 2022
FeaturedNews Batavia enters the commercial manufacturing business Leiden, The Netherlands, June 28, 2022 – Today, Batavia Biosciences announces that it will extend…Aaron Ogdahl28 June 2022